The ETOP IBCSG Partners Foundation conducts translational research as defined by the Translational Research Working Group (TRWG). Recent reports have focused on the role of centrally-assessed estrogen receptor, progesterone receptor, Ki-67, Her2, skp2, and p27 in prognosis and treatment response. These parameters, along with other clinical and pathological features, are available for merging with new tumor characteristics that may be developed and approved. The resulting databases are rich in information on tumor characteristics as well as long-term follow-up.

Researchers can apply to the ETOP IBCSG Partners Foundation Translational Research Coordinator for the use of FFPE breast cancer specimens. The Tissue Bank Materials Availability Report provides an overview of the collected and available material for the relevant ETOP IBCSG Partners Foundation Trials. The Translational Research Working Group is in charge of assessing the scientific aspects and the priority of each project.

For approved projects, the Principal Investigator of the research facility which will examine the specimens allocated for the project must sign an agreement with ETOP IBCSG Partners Foundation on confidentiality, data and material transfer, and collaboration with the Statistical Center in correlating biomolecular findings with clinical data.

Documents to download:
Letter of Intent for Research Proposal
Availability of material in ETOP IBCSG Partners Biobank
Guidelines for Publications and Presentations of IBCSG Trials v2.2 Dec 2022

Please address letter of intents for research proposals to:

Rosita Kammler
ETOP IBCSG Partners Foundation
Head Translational Research Coordinator
Effingerstrasse 33
3008 Berne
Switzerland
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.